CD20-depleting therapy in autoimmune diseases: From basic research to the clinic

Journal of Internal Medicine

Volumn 267, Issue 3, 2010, Pages 260-277

  Perosa, F ^a   Prete, M ^a   Racanelli, V ^a   Dammacco, F ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Autoimmune diseases; CD20; Immunotherapy; Monoclonal antibodies; Target antigen

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; ANCA ASSOCIATED VASCULITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTHRALGIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TOXICITY; BRONCHITIS; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CRYOGLOBULINEMIA; CYTOMEGALOVIRUS INFECTION; DERMATOMYOSITIS; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION REACTION; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; INFECTION; INFECTIOUS PNEUMONIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MICROSCOPIC POLYANGIITIS; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; OPTIMAL DRUG DOSE; PANCYTOPENIA; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; POLYMYOSITIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN STRUCTURE; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPTICEMIA; SERUM SICKNESS; SIDE EFFECT; SINUSITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYPHYLAXIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASCULITIS; VIRUS INFECTION; WEGENER GRANULOMATOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; MICE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 75749148783     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2009.02207.x     Document Type: Review

References (153)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975 256 : 495 497.
2. Meeker TC, Lowder J, Maloney DG et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985 65 : 1349 1363.
3. Houot R, Levy R. Idiotype vaccination for lymphoma: moving towards optimisation. Leuk Lymphoma 2009 50 : 1 2.
4. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007 44 : 3823 3837.
5. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008 4 : 557 567.
6. Fraussen J, Vrolix K, Martinez-Martinez P et al. B cell characterization and reactivity analysis in multiple sclerosis. Autoimmun Rev 2009 8 : 654 658.
7. Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 1998 161 : 3242 3248.
8. Teeling JL, Mackus WJ, Wiegman LJ et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006 177 : 362 371.
9. Polyak MJ, Ayer LM, Szczepek AJ, Deans JP. A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. Leukemia 2003 17 : 1384 1389.
10. Cragg MS, Morgan SM, Chan HT et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003 101 : 1045 1052.
11. Li H, Ayer LM, Polyak MJ et al. The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism. J Biol Chem 2004 279 : 19893 19901.
12. Leveille C, Al-Daccak R, Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur J Immunol 1999 29 : 65 74.
13. Walshe CA, Beers SA, French RR et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J Biol Chem 2008 283 : 16971 16984.
14. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993 121 : 1121 1132.
15. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002 107 : 176 182.
16. Chan HT, Hughes D, French RR et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003 63 : 5480 5489.
17. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004 103 : 2738 2743.
18. Ivanov A, Beers SA, Walshe CA et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009 119 : 2143 2159.
19. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002 99 : 3256 3262.
20. Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 2006 107 : 1070 1077.
21. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood 2006 108 : 1975 1978.
22. Du J, Wang H, Zhong C et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J Biol Chem 2007 282 : 15073 15080.
23. Perosa F, Favoino E, Vicenti C et al. Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes. J Immunol 2009 182 : 416 423.
24. Michel RB, Mattes MJ. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res 2002 8 : 2701 2713.
25. Ghetie MA, Crank M, Kufert S, Pop I, Vitetta E. Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts. J Immunother 2006 29 : 536 544.
26. Uchida J, Lee Y, Hasegawa M et al. Mouse CD20 expression and function. Int Immunol 2004 16 : 119 129.
27. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005 24 : 2121 2143.
28. Bezombes C, Grazide S, Garret C et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004 104 : 1166 1173.
29. Lee EJ, Kueck B. Rituxan in the treatment of cold agglutinin disease. Blood 1998 92 : 3490 3491.
30. Ratanatharathorn V, Carson E, Reynolds C et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000 133 : 275 279.
31. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985 314 : 537 539.
32. Le PL, Devauchelle V, Pers JO, Jamin C, Youinou P. The mosaic of B-cell subsets (with special emphasis on primary Sjogren's syndrome). Autoimmun Rev 2007 6 : 149 154.
33. Peng SL. Altered T and B lymphocyte signaling pathways in lupus. Autoimmun Rev 2009 8 : 179 183.
34. Liu K, Mohan C. Altered B-cell signaling in lupus. Autoimmun Rev 2009 8 : 214 218.
35. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999 189 : 1639 1648.
36. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005 52 : 501 513.
37. Bugatti S, Codullo V, Caporali R, Montecucco C. B cells in rheumatoid arthritis. Autoimmun Rev 2007 7 : 137 142. (Pubitemid 350116726)
38. Anolik JH, Barnard J, Owen T et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007 56 : 3044 3056.
39. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007 3 : 86 95.
40. Protheroe A, Edwards JC, Simmons A, Maclennan K, Selby P. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology (Oxford) 1999 38 : 1150 1152.
41. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005 4 : 526 531.
42. Carbone J, Escudero A, Mayayo M et al. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency. Ann N Y Acad Sci 2005 1051 : 666 671.
43. El-Shanawany TM, Williams PE, Jolles S. Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab. J Clin Pathol 2007 60 : 715 716.
44. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004 350 : 2572 2581. (Pubitemid 38758544)
45. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006 54 : 1390 1400.
46. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 54 : 2793 2806.
47. Smolen JS, Keystone EC, Emery P et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007 66 : 143 150.
48. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007 46 : 626 630.
49. Caporali R, Caprioli M, Bobbio-Pallavicini F, Bugatti S, Montecucco C. Long term treatment of rheumatoid arthritis with rituximab. Autoimmun Rev 2009 8 : 591 594.
50. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008 58 : 2993 2999.
51. Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ. Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 2003 49 : 394 398.
52. Harner KC, Jackson LW, Drabick JJ. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome. Rheumatology (Oxford) 2004 43 : 1309 1310.
53. Dass S, Bowman SJ, Vital EM et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008 67 : 1541 1544.
54. Pijpe J, van Imhoff GW, Spijkervet FK et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005 52 : 2740 2750.
55. Pijpe J, van Imhoff GW, Vissink A et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis 2005 64 : 958 960.
56. Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross WL. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 2005 64 : 1087 1088.
57. Gottenberg JE, Guillevin L, Lambotte O et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005 64 : 913 920.
58. Ring T, Kallenbach M, Praetorius J, Nielsen S, Melgaard B. Successful treatment of a patient with primary Sjogren's syndrome with Rituximab. Clin Rheumatol 2006 25 : 891 894.
59. Touma Z, Sayad J, Arayssi T. Successful treatment of Sjogren's syndrome with rituximab. Scand J Rheumatol 2006 35 : 323 325.
60. Yamout B, El-Hajj T, Barada W, Uthman I. Successful treatment of refractory neuroSjogren with Rituximab. Lupus 2007 16 : 521 523.
61. Seror R, Sordet C, Guillevin L et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007 66 : 351 357.
62. Devauchelle-Pensec V, Pennec Y, Morvan J et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007 57 : 310 317.
63. Isaksen K, Jonsson R, Omdal R. Anti-CD20 treatment in primary Sjogren's syndrome. Scand J Immunol 2008 68 : 554 564.
64. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005 52 : 601 607.
65. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007 56 : 3107 3111.
66. Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007 56 : 148 153.
67. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007 34 : 1864 1868.
68. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006 33 : 1021 1026.
69. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007 143 : 763 767.
70. Feist E, Dorner T, Sorensen H, Burmester GR. Longlasting remissions after treatment with rituximab for autoimmune myositis. J Rheumatol 2008 35 : 1230 1232.
71. Cambridge G, Leandro MJ, Teodorescu M et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006 54 : 3612 3622.
72. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002 46 : 2673 2677.
73. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004 50 : 2580 2589.
74. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005 44 : 1542 1545.
75. Marks SD, Patey S, Brogan PA et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005 52 : 3168 3174.
76. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006 8 : R83.
77. Willems M, Haddad E, Niaudet P et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006 148 : 623 627.
78. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006 54 : 2970 2982.
79. Tokunaga M, Saito K, Kawabata D et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007 66 : 470 475.
80. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007 56 : 1263 1272.
81. Tanaka Y, Yamamoto K, Takeuchi T et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007 17 : 191 197.
82. Lu TY, Ng KP, Cambridge G et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: the first fifty patients. Arthritis Rheum 2009 61 : 482 487.
83. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007 66 : 1259 1262.
84. Marks SD, Tullus K. Successful outcomes with rituximab therapy for refractory childhood systemic lupus erythematosus. Pediatr Nephrol 2006 21 : 598 599.
85. Racanelli V, Sansonno D, Piccoli C, D'Amore FP, Tucci FA, Dammacco F. Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus-infected patients. J Immunol 2001 167 : 21 9.
86. Landau DA, Saadoun D, Calabrese LH, Cacoub P. The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun Rev 2007 6 : 581 587.
87. Zaja F, De Vita S, Russo D et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 2002 46 : 2252 2254.
88. Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 1999 84 : 1157 1158.
89. Zaja F, Vianelli N, Sperotto A et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003 44 : 1951 1955.
90. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003 101 : 3818 3826.
91. Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008 20 : 23 8.
92. Roccatello D, Baldovino S, Rossi D et al. Rituximab as a Therapeutic Tool in Severe Mixed Cryoglobulinemia. Clin Rev Allergy Immunol 2008 34 : 111 117.
93. Visentini M, Granata M, Veneziano ML et al. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 2007 125 : 30 3.
94. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008 67 : 283 287.
95. Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003 101 : 3827 3834.
96. Saadoun D, Resche-Rigon M, Sene D, Perard L, Karras A, Cacoub P. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 2008 67 : 1431 1436.
97. Russell KA, Specks U. Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon Rheum Dis Clin North Am 2001 27 : 815 832. vii.
98. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005 257 : 540 548.
99. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005 52 : 262 268.
100. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006 173 : 180 187.
101. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006 45 : 1432 1436.
102. Aries PM, Hellmich B, Voswinkel J et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006 65 : 853 858.
103. Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007 25 : S23 7.
104. Henes JC, Fritz J, Koch S et al. Rituximab for treatment-resistant extensive Wegener's granulomatosis - additive effects of a maintenance treatment with leflunomide. Clin Rheumatol 2007 26 : 1711 1715.
105. Roccatello D, Baldovino S, Alpa M et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008 26 : S67 71.
106. Lovric S, Erdbruegger U, Kumpers P et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 2009 24 : 179 185.
107. Karpatkin S. Autoimmune (idiopathic) thrombocytopenic purpura. Lancet 1997 349 : 1531 1536.
108. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001 98 : 952 957.
109. Giagounidis AA, Anhuf J, Schneider P et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002 69 : 95 100.
110. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003 78 : 1340 1346.
111. Cooper N, Stasi R, Cunningham-Rundles S et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004 125 : 232 239.
112. Braendstrup P, Bjerrum OW, Nielsen OJ et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005 78 : 275 280.
113. Zaja F, Vianelli N, Battista M et al. Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 2006 34 : 571 572.
114. Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol 2007 86 : 871 877.
115. Medeot M, Zaja F, Vianelli N et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. Eur J Haematol 2008 81 : 165 169.
116. Godeau B, Porcher R, Fain O et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008 112 : 999 1004.
117. Parodi E, Rivetti E, Amendola G et al. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Br J Haematol 2009 144 : 552 558.
118. Alasfoor K, Alrasheed M, Alsayegh F, Mousa SA. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). Ann Hematol 2009 88 : 239 243.
119. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007 92 : 1695 1698.
120. Zaja F, Battista ML, Pirrotta MT et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 2008 93 : 930 933.
121. Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007 146 : 25 33.
122. Takemoto CM. Rituximab for ITP: a long-term fix? Pediatr Blood Cancer 2009 52 : 155 156.
123. Petz LD. Treatment of autoimmune hemolytic anemias. Curr Opin Hematol 2001 8 : 411 416.
124. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le DF, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001 358 : 1511 1513.
125. Zecca M, Nobili B, Ramenghi U et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003 101 : 3857 3861.
126. Ramanathan S, Koutts J, Hertzberg MS. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab. Am J Hematol 2005 78 : 123 126.
127. D'Arena G, Califano C, Annunziata M et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur J Haematol 2007 79 : 53 8.
128. Bussone G, Ribeiro E, Dechartres A et al. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol 2009 84 : 153 157.
129. Fairweather H, Tuckfield A, Grigg A. Abbreviated dose rituximab for immune-mediated hematological disorders. Am J Hematol 2008 83 : 554 557.
130. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006 355 : 1772 1779. (Pubitemid 44631360)
131. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005 153 : 620 625.
132. Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol 2007 156 : 990 996.
133. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 2007 143 : 1033 1038.
134. Joly P, Mouquet H, Roujeau JC et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007 357 : 545 552.
135. Fernando SL, O'Connor KS. Treatment of severe pemphigus foliaceus with rituximab. Med J Aust 2008 189 : 289 290.
136. Sorce M, Arico M, Bongiorno MR. Rituximab in refractory pemphigus vulgaris. Dermatol Ther 2008 21 (Suppl. 1 S6 9.
137. Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol 2008 47 : 292 294.
138. Diab M, Bechtel M, Coloe J, Kurtz E, Ranalli M. Treatment of refractory pemphigus erythematosus with rituximab. Int J Dermatol 2008 47 : 1317 1318.
139. Serrao VV, Martins A, Paris FR, Lopes MP. Successful treatment of recalcitrant pemphigus foliaceus with rituximab. J Eur Acad Dermatol Venereol 2008 22 : 768 770.
140. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009 68 : 25 32.
141. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 295 : 2275 2285.
142. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001 344 : 68 9.
143. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001 345 : 1000.
144. Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000 85 : 894 895.
145. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000 96 : 1184 1186.
146. Basse G, Ribes D, Kamar N et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006 38 : 2308 2310.
147. Egli A, Infanti L, Dumoulin A et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009 199 : 837 846.
148. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009 113 : 4834 4840.
149. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007 56 : 2116 2128.
150. Major EO. Reemergence of PML in natalizumab-treated patients - new cases, same concerns. N Engl J Med 2009 361 : 1041 1043.
151. Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008 67 (Suppl 3 iii64 5.
152. Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009 115 : 229 232.
153. Andrei G, De CE, Snoeck R. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? Antiviral Res 2004 61 : 181 187.